Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
M.D. Anderson Cancer Center
Summary
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Description
Primary Objectives: 1\. To estimate overall survival in patients with recurrent ovarian clear cell carcinoma being treated with LB-100 and dostarlimab, including specific survival probabilities at 6 and 12 months. Secondary Objectives: 1. To describe clinically significant and immune related adverse events (ir-AEs) in the study population. 2. To determine the objective response rate (ORR), time to initial response, progression free survival (PFS), and duration of response (DOR) using modified RECIST v1.1 criteria. a. Although the clinical benefit of these drugs has not yet been establis…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Inclusion criteria will be assessed within 28 days of starting study treatment: 1. Ability to provide signed informed consent 2. Age 18-75 years at time of study entry 3. Willingness and ability to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up 4. Histology showing recurrent clear cell ovarian, peritoneal, or fallopian tube cancer (mixed histology with predominant clear cell component is acceptable). 5. Receipt of at least one prior line of therapy for recurrent disease or dev…
Interventions
- DrugDostarlimab
Given by vein (IV)
- DrugLB-100
GIven by vein (IV)
Location
- M D Anderson Cancer CenterHouston, Texas